Corbus Pharmaceuticals (CRBP) has released an update to notify the public and investors about a regulation fd disclosure.
On January 30, 2024, the Company publicized the initiation of an Offering and followed up the next day announcing its pricing. The press releases are included in their current report. The report contains forward-looking statements regarding the expected closing and proceeds of the Offering, which are subject to risks and uncertainties that could affect the Company’s ability to close the Offering as anticipated. These risks are outlined in the Company’s SEC filings, including their annual and the Offering-related prospectus supplements.
For further insights into CRBP stock, check out TipRanks’ Stock Analysis page.
For a comprehensive understanding of the announcement, you can read the full document here.
